Clinical Research Papers:
Feasibility of using stereotactic body radiation therapy for unresectable soft tissue tumors of the trunk
Metrics: PDF 713 views | HTML 1056 views | ?
Eun Kyung Paik1, Mi-Sook Kim1, Chul-Koo Cho1, Hyung Jun Yoo1, Won Il Jang1, Young-Seok Seo2, Sung-Ho Jin3, Dae Geun Jeon4 and Dong Han Lee5
1Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
2Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
3Department of Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
4Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
5CyberKnife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
Mi-Sook Kim, email: firstname.lastname@example.org
Keywords: soft tissue tumor; sarcoma; stereotactic body radiation therapy; unresectable; trunk
Received: September 07, 2017 Accepted: May 17, 2018 Published: June 12, 2018
Purpose: To evaluate the feasibility of stereotactic body radiation therapy (SBRT) for unresectable soft tissue tumors of the trunk.
Materials and Methods: Between January 2002 and December 2008, 23 patients with 36 lesions of soft tissue tumors, which were located in the trunk and not suitable for resection, underwent SBRT. Among the 36 lesions, 31 were malignant and 5 were benign. The median tumor volume was 24 cm3 (range, 2.6–213 cm3). SBRT doses ranged from 20 to 48 Gy in 1–5 fractions.
Results: With a median follow-up of 73 months, the overall survival (OS) and local control (LC) rates at 5 years were 39% and 52%, respectively. For malignant tumors, the OS and LC rates at 5 years were 28% and 47%, respectively. For benign tumors, the OS and LC rates at 5 years were 80% and 100%, respectively. There was no acute toxicity of grade ≥3. One case of grade 3 late skin toxicity was reported 10 months after SBRT.
Conclusion: SBRT may be an effective and safe treatment modality for the local control of unresectable soft tissue tumors of the trunk including tumors of a benign nature.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.